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1  | INTRODUC TION
As new reprogenetic technologies—such as those used to undertake 
whole genome sequencing—are becoming increasingly subsumed 
within standard National Health Service care, the possibility of their 
use as a population‐level genetic screening tool is now being consid‐
ered in earnest, both within and beyond the UK (Hasegawa, Fergus, 
Ojeda, & Au, 2011; Tarini & Goldenberg, 2012). Indeed, the perceived 
centrality of genomics to the future of medicine is reflected by its 
high position on the UK public agenda (Davies, 2016) and the doc‐
umented widespread interest, and investment, in genomic medicine 
by the UK general public (Middleton et al., 2016).
When considering the management of relatively common ge‐
netic diseases, many of which continue to lack effective treatments, 
this shift towards population‐level genomics is significant. While 
individually rare, when viewed together, the risk to the health of 
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Abstract
Members of the public face particular challenges when undergoing reproductive ge‐
netic screening. Lack of family history with genetic disease has been identified as a 
key barrier affecting screening uptake and responses to genetic risk. This study ex‐
plores this obstacle using beta thalassaemia as a case study. Fifteen in‐depth qualita‐
tive interviews were conducted exploring the reproductive views and decisions of 
people at risk of transmitting thalassaemia. Eleven participants had thalassaemia 
themselves and/or were members of an affected family. Four participants were iden‐
tified as thalassaemia carriers through genetic screening programmes with no family 
history. Notable differences were observed between these two groups. For thalas‐
saemic individuals and families, past experience clarified and facilitated their sense of 
reproductive responsibility, however carriers struggled to relate to, and incorporate 
the information into their lives. It was witnessing their child becoming symptomatic—
rather than receiving a diagnosis or genetic risk information per se that had the most 
substantial influence on carriers’ subsequent views and decisions. Educational re‐
sources used to support genetic screening programmes would benefit from an en‐
gagement with the experiential accounts of life with genetic disease in order to more 
effectively bridge the chasm in knowledge and understanding between affected 
families and the general public, towards whom expansive genetic screening is aimed.
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the public posed by such genetic disorders becomes more substan‐
tial (Archibald et al., 2018). Indeed, recent research suggests that 
when combined, the prevalence of the three most common genetic 
disorders (Cystic Fibrosis, Fragile X syndrome and Spinal Muscular 
Atrophy [SMA]) is comparable to that of Down's Syndrome (Archibald 
et al., 2018)—a condition routinely screened for within standard 
NHS antenatal care. This prevalence, when considered alongside the 
unpredictable and variable prognoses associated with many of these 
genetic disorders and their relatively 20 limited treatment options all 
contribute to the mounting case in favour of offering carrier screen‐
ing programmes to the general public (Gregg et al., 2014; Nazareth, 
Lazarin,	&	Goldberg,	2015;	Plantinga	et	al.,	2016).
Although identifying carriers of genetic conditions in the general 
population in either the pre‐conceptual or prenatal period confers 
particular opportunities for the carrier couples it identifies—primar‐
ily through the extension of their (currently limited) reproductive 
options (HGC, 2011)—this approach also brings with it practical, 
ethical and social dilemmas that may surface in genetic counselling 
contexts.
One persistent challenge identified in the literature relates to 
the receptivity of the general population to the notion of their po‐
tential carrier status (Archibald et al., 2009; Beard, Amor, Pietro, 
& Archibald, 2016; Ioannou, Delatycki, Massie, Hodgson, & Lewis, 
2015;	McClaren,	Delatycki,	Collins,	Metcalfe,	&	Aitken,	2008).	As	
NHS carrier testing has typically only been reserved for families 
already known to be affected by genetic disease, those under‐
going carrier testing have usually approached the decision in the 
context of their prior knowledge of the condition—a factor known 
to have a significant influence on reproductive decisions and at‐
titudes (Baillergeau & Duyvendak, 2016; Etcehgary et al., 2008; 
Kay & Kingston, 2002; Raspberry & Skinner, 2010; Ziebland & 
Herxheimer, 2008). Indeed, research data have revealed key dif‐
ferences in the reproductive attitudes and decisions between 
those who have (and those who lack) prior experience of the con‐
dition being tested for (Boardman, Young, Warren, & Griffiths, 
2017; Etchegary et al., 2008). Those with direct experience have 
been found to typically view the condition in a more favourable 
light than those who lack this form of insight (Boardman, Young, 
Warren, et al., 2017; Watson, Williamson, & Chapple, 1991), al‐
though this has been shown to vary according to the nature and 
impact of the condition (Kay & Kingston, 2002). Through familiar‐
ity with the challenges and opportunities associated with a par‐
ticular condition, experiential knowledge may instil confidence in 
a person's perceived ability to cope with a child with that same 
condition (Boardman, 2014). By acting as a “window” into potential 
futures, this intimate way of knowing and experiencing genetic dis‐
ease allows for the realistic envisioning, and appraisal, of different 
reproductive outcomes (Boardman, 2014; Etchegary et al., 2008; 
Markens, Browner, & Preloran, 2010) in a way that may be more 
challenging to those for whom genetic disease is a more removed 
and abstract concept (Archibald et al., 2009).
When experiential knowledge of genetic disease becomes dis‐
located from the reproductive decisions that concern it, however, 
through the practice of genetic screening, there are significant im‐
plications not only for reproductive attitudes, but also uptake of 
carrier screening in various contexts (Archibald et al., 2009, 2018; 
Ioannou et al., 2014; McClaren et al., 2008). Plantinga et al.’s (2016) 
study	of	public	attitudes	towards	the	offer	of	a	carrier	screen	for	50	
genetic disorders, for example, demonstrated that the most com‐
mon reason for lack of interest in undergoing the screen was “not 
wanting to be bothered” by the knowledge that one could be a car‐
rier	for	genetic	disease	(Plantinga	et	al.,	2016p.	5).	Similarly,	Prior	et	
al.’s (2010) study of carrier screening for SMA highlighted the most 
common	reason	for	screening	refusal	among	the	500	pregnant	or	
pre‐conceptual women offered an SMA screen was reported as a 
lack of concern about SMA. Lack of family history, already being 
a parent to healthy children, not being of advanced maternal age 
and viewing oneself as fit and healthy have all been identified as 
informing perceptions of the chances of being a genetic carrier (and 
consequently screening uptake) in spite of the irrelevance of these 
factors to actual genetic risk status (Beard et al., 2016; McClaren 
et al., 2008). Even for the most prevalent genetic diseases, public 
awareness and understanding of the nature of genetic inheritance 
remain demonstratively poor (Anido, Carlson, Taft, & Sherman, 
2005;	Braido	et	al.,	2015;	Fanos,	Spangner,	&	Musci,	2006;	Moultrie,	
Kish‐Doto, Peay, & Lewis, 2016; Watson et al., 1991) with interest 
in carrier screening correspondingly low. The only exception to this 
trend is instances where the test is offered or recommended di‐
rectly by a health care professional (Rothwell, Anderson, Swoboda, 
Stark, & Botkin, 2013).
The perception that genetic disease is only relevant to the sub‐
set of the population already living with them is further reflected 
in the reactions of shock and unpreparedness experienced by car‐
rier couples in the wake of positive screening test results (Anido 
et	al.,	2005;	Beard	et	al.,	2016;	Ioannou	et	al.,	2015).	Unlike	fami‐
lies already living with genetic disease, screening‐identified carrier 
couples need to quickly absorb large quantities of complex infor‐
mation about the condition they carry and/or make difficult deci‐
sions about pregnancy (dis)continuation, often within a compressed 
timeframe, presenting significant challenges to genetic counsellors 
(Ioannou	et	al.,	2015).
Within the UK, the carrier screening programme for thalassae‐
mia is currently the only prenatal genetic screening programme of‐
fered within standard NHS care. All pregnant women are screened 
for thalassaemia carrier status, usually before they reach 10 weeks 
gestation, and if found to be a carrier, are invited to have the father 
of the foetus tested and/or diagnostic testing of foetus, depending 
on the results.
Thalassaemia refers to a group of inherited recessive blood 
disorders that affect the production of haemoglobin within the 
body, affecting approximately 70,000 newborns annually and 
making them among the most common single trait recessive dis‐
orders worldwide (Cousens, Gaff, Metcalfe, & Delatycki, 2010). 
Approaches to thalassaemia screening vary drastically in the inter‐
national arena, with mandatory pre‐marital screening programmes 
underway in countries with particularly high prevalence (e.g., Iran, 
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Saudi Arabia, Palestinian Territories and Cyprus) (Cousens et al., 
2010). Thalassaemia carriers (also known as people with thalassae‐
mia “trait” or thalassaemia “minor”) typically do not have any serious 
associated health problems (although may be mildly anaemic), but 
have the potential to pass thalassaemia on to any future children, if 
conceived with another thalassaemia carrier. When two thalassae‐
mia carriers reproduce, each child born to them has a one in four 
chance of having thalassaemia.
The primary treatment for beta thalassaemia is regular (every 
4–6 weeks) blood transfusions to treat and prevent anaemia, usu‐
ally in conjunction with chelation therapy to treat any associated 
iron build up. The current average life expectancy (with treatment) 
of a person diagnosed with thalassaemia today is between 40 and 
50	years	old,	but	this	is	expected	to	increase	significantly	overtime	
as treatments improve (Telfer, 2009).
Whilst only one carrier screening programme is currently imple‐
mented at population level in the UK, shifts in the capacities of ge‐
nomic technologies suggest that this model of screening provision is 
likely to expand in the future. Increasing numbers of would‐be par‐
ents will be called upon to make decisions about the conditions they 
would want to know their carrier status for, and which they would 
not, often without any experience or knowledge of the conditions 
around which they are making such decisions (Plantinga et al., 2016). 
It is on account of this unfamiliarity with the world of genetics that 
proponents of pre‐conception genetic screening have highlighted 
the need for high quality information and support to provide the in‐
frastructure for any screening programmes implemented (Prior et al., 
2010), as well as a need to better understand the role and value of 
prior experience with genetic disease within reproductive decisions 
(Boardman, Young, Warren, et al., 2017).
In order to address this under‐explored topic, this paper offers 
an analytic comparison of the views, experiences and reproduc‐
tive	 decisions	 of	 15	 people	 at	 risk	 of	 transmitting	 thalassaemia	
with contrasting levels of prior experience and knowledge of the 
condition. Eleven participants approached their decision in the 
context of a family history with thalassaemia (i.e., either they had 
thalassaemia themselves or a member of their family did), and 
four participants made their reproductive decisions having been 
identified as a thalassaemia carrier through antenatal or newborn 
genetic screening, but without any prior history of, or experience 
with, the disease. The contrast between these two positions is 
illuminated in order to offer critical insight into the role that these 
disparities of knowledge and experience have on reproductive 
views and decisions, before considering their policy and practice 
implications.
2  | METHODS
This	study	involved	in‐depth	qualitative	interviews	with	15	partici‐
pants who either had prior experience of thalassaemia, or encoun‐
tered it through antenatal genetic screening.
3  | RECRUITMENT
Participants were recruited into the study through the largest sup‐
port group for thalassaemia in the UK, the UK Thalassaemia Society 
(UKTS). The UKTS offers support to people across the UK who are 
either carriers of thalassaemia, have thalassaemia themselves or 
have a diagnosis of thalassaemia in the family. Three separate calls 
were placed in the society's e‐mail delivered publication between 
June and December 2017, requesting that potential participants get 
in touch with the project researcher.
4  | INTERVIE WS
Upon initial contact with the study team, participants were provided 
with an information leaflet outlining the aims of the research and 
what their participation might involve. They were then asked to con‐
tact the researchers to arrange an interview if they remained inter‐
ested in being involved. After this point, participants were asked to 
sign a consent form, and interviews were carried out either face‐
to‐face or over the telephone, depending on participant availability, 
health needs and preference. The majority of face‐to‐face interviews 
were carried out in participants’ homes although one was conducted 
in the participant's workplace and another in a public space within a 
hotel (Table 1).
The interview schedule was developed by reference to the rel‐
evant literature, as well as the lead researcher's previous work in 
this area (Boardman, 2014; Boardman, Young, & Griffiths, 2017; 
Boardman, Young, Warren, et al., 2017). It covered participants’ prior 
experiences with thalassaemia, their perceptions of quality of life, 
TA B L E  1   Participant characteristics
Participants Numbers
Gender Ethnicity Interview type
Thalassaemia identification 
route
Female Male Asian European
Face‐to‐
face Telephone Screening Family history
Diagnosed with thalassemia 8 5 3 5 3 3 5 0 10
Parent of person diagnosed 
with thalassemia
7 5 2 7 0 2 5 4 1
Totals 15 10 5 12 3 5 10 4 11
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any reproductive decisions made or anticipated, views on selective 
reproduction and views and attitudes towards population genetic 
screening specifically for thalassaemia, as well as for other condi‐
tions. The interviews lasted on average for 43 min, with telephone 
interviews averaging 39 min duration and face‐to‐face interviews 
49 min. The range of the interviews was between 21 and 74 min. All 
interviews were audio‐recorded and transcribed verbatim by a pro‐
fessional transcription service (with names and identifiers removed).
5  | DATA ANALYSIS
A modified grounded theory approach was undertaken to analyse 
the resulting data. Initially, one researcher conducted “open coding” 
(Gibbs, 2007) which was largely descriptive, before more discrimi‐
natory hierarchical coding was undertaken using qualitative data 
analysis software, Nvivo 11. Both researchers were involved in hier‐
archical coding through a process of coding and refinement of con‐
cepts (through data interpretation, reference to the literature and 
regular analysis meetings between the researchers). Discrepancies 
in coding were discussed between the researchers and following 
agreement, re‐coding was carried out until “theoretical saturation” 
(i.e., no new concepts were emerging) had occurred.
6  | PRESENTATION OF RESULTS
Although	15	participants	were	interviewed	and	an	analysis	of	all	of	
their accounts contributed to the thematic framework, four partici‐
pants have been selected for detailed presentation within this paper. 
These four accounts were selected on the basis of their particularly 
eloquent representation of the views and experiences of other par‐
ticipants within the two groups (those who had prior experience 
with thalassaemia or those who encountered it though antenatal/
newborn genetic screening) Moreover, as the concept of experien‐
tial knowledge is so critical to this analysis, a focus on the narratives 
of four participants allows for a more detailed and nuanced explora‐
tion of participants’ stories and their relationship to their reproduc‐
tive decisions and attitudes, which would not have been possible in 
detail	 for	 all	 15	 participants.	 To	 protect	 the	 identities	 of	 the	 four	
participants, all names appearing within this paper are pseudonyms.
E THIC AL APPROVAL
Ethical approval for the research was granted by The University of 
Warwick's Biomedical and Scientific Research Ethics Committee on 
4th April 2017 (REGO‐2017)
8  | RESULTS
The calls for participants resulted in contact from 21 people which 
in	turn	led	to	the	successful	completion	of	15	interviews.	Six	people	
who initially made contact with the research team were not inter‐
viewed as attempts to arrange an interview were unsuccessful. After 
two attempts to arrange an interview with each person, further 
contact was abandoned. One participant contacted the team for in‐
terview after the completion of the analysis and was accepted for in‐
terview. Their transcript was analysed using the thematic framework 
developed from the previous interviews.
The	15	participants	who	went	through	for	interview	either	had	
thalassaemia themselves, or had at least one person diagnosed with 
thalassaemia in their family (see Table 2). All of the four participants 
who were identified as thalassaemia carriers through genetic screen‐
ing went on to have at least one child with thalassaemia.
Participants	 ranged	 in	 age	 from	 25	 to	 68,	 nine	 were	 parents	
and seven of these were parents to a child/children with thalassae‐
mia, with one participant having multiple affected children (Jahida) 
(see Table 2). Only two of the nine parents had thalassaemia them‐
selves (Bilal and Imran), both were male, and neither had gone on 
to have affected children themselves (Table 2). The vast majority of 
participants were female (10), and all were of South‐Asian, South‐
East Asian or Mediterranean heritage, reflecting the typical ethnic 
prevalence of thalassaemia (Hickman et al., 1999). All participants 
described themselves as belonging to a religious community (see 
Table 2), however, four participants described this as reflecting their 
social identity rather than their personal beliefs. The participants 
were geographically dispersed throughout England.
The results have been divided into two sections depending on 
participants’ prior experiences with thalassaemia. First, the accounts 
of participants who considered their reproductive views through the 
lens of an established family or personal history with thalassaemia 
will be presented (n = 11), before contrasting these with the ac‐
counts of those who discovered the condition in their family through 
genetic screening (n = 4).
8.1 | ‘I know exactly how hard it can become…’: 
Experiential knowledge and reproduction in 
thalassaemic families
For the majority of participants within the sample (11), thalassae‐
mia was a condition for which they had considerable experience 
to draw on as they considered their own reproductive views and 
decisions. Eight of these participants had thalassaemia themselves 
(with two, Giovanni and Imran, also having an affected sibling), and 
two were parents of an affected child who had not been identified 
prenatally (Jamini and Chaaya). For these participants, considering 
their own reproductive attitudes and decisions (both past and an‐
ticipated) was inextricably linked to the everyday reality of life with 
thalassaemia.
Imran	was	 a	45	year	old	man	at	 the	 time	of	his	 interview,	 and	
had been diagnosed with thalassaemia shortly after birth. He was 
living and working part‐time as a taxi driver in an English city, and 
had five children (all carriers of thalassaemia, but without the condi‐
tion themselves) born through an arranged marriage that Imran de‐
scribed as having since broken down. Imran described thalassaemia 
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as a sceptre that had overshadowed much of his life, contributing to 
him being “overlooked” and “written off” within his family. He de‐
scribed there being accepted belief within his family that he would 
not	live	past	the	age	of	25,	a	view	that	when	combined	with	his	fam‐
ily's Muslim faith contributed to the pressure Imran felt to accept an 
arranged marriage:
I was pushed into an arranged marriage. And the ex‐
cuses they were giving me at the time was I going to be 
dead	by	the	age	of	25,	so	you	need	to	have…	“get	mar‐
ried and have children so that God is happy with you”. 
And it wasn't just my parents saying this, it was my 
brothers, and I have a big family. And then at the time I 
was working in my uncle's restaurant, so I was getting 
it from my uncle as well, so there was huge pressure, 
peer pressure, family pressure to just go along with it.
For Imran, becoming educated about his thalassaemia in his early 
30 s (by joining support groups and meeting other people with the 
same diagnosis) and becoming more proactive in its management, as 
well as “coming out” as a gay man were critical turning points in his 
life. Up until that point, his life had very much been under the control 
of a heavily stigmatised and disabling condition that he did not fully 
understand and an influential family with very particular ideas about 
how best to offset the disadvantages his condition was seen to impose.
Indeed, it was Imran's overwhelmingly negative experiences with 
thalassaemia and the reactions to it of those around him that invari‐
ably influenced his views of it as a condition as well as his percep‐
tions of reproductive morality:
I	 resent	 that	 I	was	born	with	 thalassaemia	actually…
[…]…	 I've	 seen	my	 fair	 share	of	 suffering	and	 I	don't	
think	parents	should	even	be	given	the	choice….[…]…	
you	know…I	think	thalassaemia	should	be	eradicated	
and the government should be forcing Asian parents 
to stop their children marrying within the family just 
for the property, and also to have screening before 
marriage, like they did in Greece, you know? If some‐
one	 had…	 if	 two	 carriers,	 if	 two	 people	 are	 carriers	
they shouldn't be allowed to have children, simple 
as that. But if they have the pregnancy and there are 
stem cells or that kind of thing that can be done in the 
pregnancy then, fine, the baby can live, but if there's 
no cure while the baby's in pregnancy then I think it 
should	be	terminated,	yeah.	I	think	that's	kinder….But	
I'm quite a bit radical, people probably would object to 
me being radical, but I'm sorry you don't know my life 
and as far as I'm concerned I don't wish this on anyone.
The attitudes of people with genetic disorders towards carrier 
or prenatal screening for the same disorder they have has been rel‐
atively under‐explored in the literature (Boardman, 2014), however, 
recent studies produce a somewhat contradictory picture, with T
A
B
L
E
 2
 
Pa
rt
ic
ip
an
t e
xp
er
ie
nc
e 
w
ith
 th
al
as
sa
em
ia
 a
nd
 s
cr
ee
ni
ng
Pa
rt
ic
ip
an
t n
um
be
r
Ps
eu
do
ny
m
A
ge
Se
x
Et
hn
ic
ity
R
el
ig
io
n/
re
lig
io
us
 
co
m
m
un
ity
Pa
re
nt
al
 
st
at
us
N
um
be
r o
f c
hi
ld
re
n 
w
ith
 th
al
as
se
m
ia
N
at
ur
e 
of
 e
xp
er
ie
nc
e 
w
ith
 th
al
as
sa
em
ia
H
ow
 t
ha
la
ss
ae
m
ia
 w
as
 
di
sc
ov
er
ed
1
Bi
la
l
46
M
A
si
an
 (P
ak
is
ta
n)
M
us
lim
✔
0/
5
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
2
M
ah
ila
36
F
A
si
an
 (L
eb
an
es
e)
C
at
ho
lic
0
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
3
A
m
ee
na
38
F
A
si
an
 (B
rit
is
h 
In
di
an
)
M
us
lim
✔
1/
4
C
ar
rie
r
A
nt
en
at
al
 c
ar
rie
r s
cr
ee
ni
ng
4
G
io
va
nn
i
36
M
Eu
ro
pe
an
 (I
ta
lia
n)
C
at
ho
lic
0
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
5
Ja
hi
da
33
F
A
si
an
 (P
ak
is
ta
n)
M
us
lim
✔
3/
3
C
ar
rie
r
A
nt
en
at
al
 c
ar
rie
r s
cr
ee
ni
ng
6
Im
ra
n
45
M
A
si
an
M
us
lim
✔
0/
5
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
7
H
am
id
25
F
A
si
an
 (I
ra
ni
an
)
M
us
lim
0
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
8
In
as
36
F
A
si
an
 (B
an
gl
ad
es
h)
M
us
lim
0
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
9
D
ee
ba
49
F
A
si
an
 (P
ak
is
ta
n)
M
us
lim
✔
1/
2 
(a
do
pt
ed
)
Pa
re
nt
 o
f a
do
pt
ed
 c
hi
ld
Sy
m
pt
om
s
10
C
ha
ay
a
68
F
A
si
an
 (B
rit
is
h 
In
di
an
)
H
in
du
✔
1/
1
C
ar
rie
r
C
hi
ld
's 
Sy
m
pt
om
s
11
Ja
m
in
i
52
M
A
si
an
 (B
rit
is
h 
In
di
an
)
H
in
du
✔
1/
2
C
ar
rie
r
C
hi
ld
's 
Sy
m
pt
om
s
12
Lu
na
44
F
Eu
ro
pe
an
 (S
ar
di
ni
an
)
C
at
ho
lic
/A
gn
os
tic
0
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
13
M
ar
in
a
35
F
Eu
ro
pe
an
 (G
re
ek
 C
yp
rio
t)
G
re
ek
 O
rt
ho
do
x
0
H
as
 th
al
as
sa
em
ia
Sy
m
pt
om
s
14
Fa
dw
a
40
F
A
si
an
 (P
ak
is
ta
ni
)
M
us
lim
✔
1/
2
C
ar
rie
r
N
ew
bo
rn
 s
cr
ee
ni
ng
15
A
rju
n
41
M
A
si
an
 (B
rit
is
h 
Pa
ki
st
an
i)
M
us
lim
✔
1/
4
C
ar
rie
r
A
nt
en
at
al
 c
ar
rie
r s
cr
ee
ni
ng
6  |     BOARDMAN AND HALE
some showing support, and others more ambivalent or negative 
attitudes towards reproductive genetic medicine (Barter, Hastings, 
Williams, & Huws, 2016; Janssens et al., 2016; Roadhouse et al., 
2018). For Imran, thalassaemia, which he referred to as “the giant’ in 
his life, was at the root of much of the unhappiness, social exclusion 
and physical suffering that he described as marring his formative 
years. It was this intimate, first‐hand experience of the condition 
which he felt gave him both the authority—but also the authentic‐
ity (‘I'm sorry but you don't know my life’)—with which to promote 
state‐controlled approaches to genetic screening. However, not all 
participants” views were as clear‐cut as Imran's, with some viewing 
their detailed knowledge and experience with thalassaemia as more 
of a double‐edged sword in the context of reproductive genetics.
Mahila was 36 years old at the time of interview and living in an 
inner‐city area in England with her husband, Haneef. She was work‐
ing full time for a charity and was, undergoing fertility treatment 
to have her first child. Mahila was diagnosed with thalassaemia at 
the age of 6 months in Lebanon, her country of birth and where she 
spent her first 20 years. She described her experience of growing up 
in Lebanon as “difficult” and “isolating” given the limited understand‐
ing around thalassaemia, the absence of contact with other children 
with the same diagnosis and the prevalent social stigma of genetic 
disease, which became more pronounced overtime. For Mahila, re‐
lationships were a key area where the stigma of her genetic disease 
was most keenly felt:
Relationship wise, in Lebanon with the Lebanese 
mentality,	 and	 I	 guess…mum	 and	 dad	 were	 not	 as	
aware of the taboo and the stigma, when I was very 
little….But…[…]….	at	some	point	mum	started	getting	
a hint of, with the Lebanese mentality is she going to 
find…	if	she	wants	to	get	married	is	she	going	to	find	a	
man who is strong enough to say to his family, “this is 
what I want”? And I think she started thinking‐ prob‐
ably not. And I didn't know at that point why she was 
telling me these things because I was quite young, but 
I	 remember	 being	 a	 teenager…and	 my	 mum	 telling	
me…	 “you	don't	 need	 a	man	 in	 your	 life,	 and	 if	 you	
want to have children there are ways to have children 
without a man.” Now I understand.
While not specifically asked about, the stigma of living with a 
genetic haemoglobinopathy was spontaneously mentioned by five 
of the 11 participants in this group, highlighting its significance in 
shaping experiences of the condition, particularly among particular 
ethnic groups where arranged marriages and family prestige are a 
central part of religious, cultural and social life (Roy & Chatterjee, 
2007;	Shaw	&	Hurst,	2006;	van	der	Wal	et	al.,	2015).	Indeed,	Mahila	
described her first boyfriend's family rejecting her as the potential 
long‐term partner for their son on account of her “defective gene” 
as an “awful” experience that informed her later attitudes towards 
relationships. Like Imran, Mahila described the people around her 
as having low expectations of her life, reinforced by her periods of 
frequent illness (which she described as increasing in frequency as 
she has gotten older) and her secondary infertility. Despite these 
experiences, however, and unlike Imran, Mahila still described 
thalassaemia as having a positive (and continuing) role in shaping her 
identity and personality:
….in	 some	 ways	 it	 has	 really	 helped	 me	 shape	 my	
personality. Because I was outside the general pack 
of	teenagers	I…	yes,	 it	was	difficult,	but	at	the	same	
time I think it gave me the impetus to be me, and very 
early on I decided I think, I'm going to be very much an 
individual who makes her own decision, who doesn't 
follow	societal	norms,	who…	it	gave	me	a	lot	of	indi‐
vidualism. And I think you can see it in my life choices 
a	 little	 bit,	 you	 know,	 in	 Lebanon	 you…	 I	was	doing	
very well academically and when we do very well ac‐
ademically in Lebanon you try to go for medicine and 
try	 and	 go	 for	 legal…there's	 a	 certain	 expectation…
[…]…And	 I	 went,	 “yeah	 I	 want	 to	 do	 charity	 work”,	
which is considered a weird choice for someone who 
was performing well academically. So I think that 
coming to terms with my difference early on in those 
teenage years kind of shaped me.
Shakespeare (2006), among others (Boardman, Young, Warren, et 
al., 2017; De Wolfe, 2002), have highlighted the contrast in outlook 
and attitude between disabled people who have fixed, static impair‐
ments (often present from birth) and those with acquired, fluctuating 
or degenerative impairments which typically involve periods of pain, 
suffering and illness (p. 106). He has argued that people who fall within 
the latter group are far more likely to experience their impairment 
as intrusive, burdensome and entirely separate from their sense of 
self and identity than those whose impairments are fixed and stable. 
Although thalassaemia might be considered a fluctuating impairment 
according to Shakespeare's categorisations, involving frequent periods 
of illness and medical treatment, Mahila's account demonstrates the 
way in which, though her condition varied, her experience of stigmati‐
sation, of being a “tainted” person (Goffman, 1963) remained constant 
and impacted the contribution thalassaemia made to the constitution 
of her identity in numerous ways. By setting her apart from the norms 
and expectations of a typical Lebanese woman, Mahila felt empow‐
ered to develop her own sense of identity and self that she might not 
otherwise had the autonomy to do.
Viewing thalassaemia in this way (as simultaneously providing 
opportunities for individualism as well as the challenges of ostra‐
cisation and exclusion) and knowing the condition intimately, how‐
ever, left Mahila with difficult decisions when approaching her own 
reproductive decisions. Her (now) husband, Haneef, underwent pre‐
marital genetic screening for thalassaemia prior to their wedding and 
was found not to be a carrier, although Mahila described their lack of 
control over this screen, with it being conducted in Lebanon where 
such screening is a marital prerequisite. Mahila described her current 
attitude to thalassaemia screening in the following way:
     |  7BOARDMAN AND HALE
….I	kind	of	asked	Haneef	this	two	days	ago	I	said,	sup‐
pose we had a child and we knew, we tested it and 
we knew that the child had thalassaemia he said, “so 
you manage it, I would have probably gone for it.” So 
it's	ambivalent	right?...[…]….Thalassaemia	is	a	difficult	
one I think because, because I have it and I've man‐
aged	 it	 and	 you	 go,	 ‘it's	 not	 that	 bad,	 it's	 bad….	 it's	
not as bad as that’, so then you think, why go through 
an	abortion	really?…You	know,	it's	not	the	end	of	the	
world and it's a manageable condition, and science is 
improving day after day. And so for us it's not maybe a 
good enough reason to let a pregnancy go. However, 
and having said all that, my first instinct would still 
be	to	have	an	abortion…	because	I	know	exactly	how	
hard it can become.
Even as Mahlia's experiential knowledge served to reassure her 
that having a child with thalassaemia would not be the “end of the 
world” because she had “managed”, she simultaneously acknowl‐
edged the more difficult parts of life with thalassaemia “how hard 
it can become”, resulting in ambivalent and contradictory feelings 
regarding the potential transmission of thalassaemia to future 
generations. This finding is mirrored by the literature on attitudes 
towards screening among people with genetic/chromosomal dis‐
orders (Boardman, 2011; Boardman, Young, Warren, et al., 2017; 
Chen & Schiffman, 2000; Middleton, Hewison, & Mueller, 1998). 
Although Mahila's experiential knowledge gave her a unique 
standpoint from which to appraise the life of any future child with 
thalassaemia, she also acknowledged the limits on how far this 
knowledge could be transposed onto the lives of future genera‐
tions in a meaningful way:
In my younger years, into my like twenties I was fine. 
I think it's now, in my thirties, that I've started real‐
ising that‐ and I hadn't realised this before‐ that as 
you grow older it actually becomes a little bit harder 
because	 your	 body	 is	 growing	 older…[…]…The	most	
concerning aspect of thalassaemia for me – and I'm 
talking personally, not in general – personally it's just 
literally that I am making it up as I go along. I've not 
been	 through	 being	 40	 with	 thalassaemia,	 50	 with	
thalassaemia, 60 with thalassaemia‐ I don't know 
what's going to come, all I can do is try and take as 
good care of myself as I can, but that is definitely the 
most concerning aspect for me.
Although Mahila had previously described her experiential knowl‐
edge as being instrumental to the way she and Haneef approached re‐
progenetic decision‐making, allowing them to feel more comfortable 
with the idea of having a thalassaemic child than they might other‐
wise have been, her experiences of growing older with thalassaemia 
also highlighted to her the parts of the thalassaemia trajectory that 
Mahila's experiential expertise could not yet reach. The shifting nature 
of her experiences brought into critical relief the intrinsic limitations 
of this type of knowledge when used as a measure of disease severity 
and projected quality of life for future generations (Boardman, 2017). 
While on the one hand giving them privileged insight into the disor‐
der, experiential knowledge also emerged from Mahila's account as a 
bounded form of insight, both limited, and contoured, by the unique 
set of circumstances through which it was generated.
Despite its inherent limitations, there was nevertheless evidence 
from all of the 11 participants who had direct experience of thalas‐
saemia in their family that their experiences served as the yardstick 
by which future lives could be anticipated and appraised. For some 
of these participants, this insight both bolstered and authenticated 
their views and decisions (e.g., Imran), whether this be to prevent 
the recurrence of thalassaemia, or a belief that thalassaemia was 
an insufficient justification for the use of genetic technologies and 
pregnancy termination. However, for the remaining participants, 
experience of thalassaemia introduced new layers of ambiguity and 
uncertainty into their reproductive views, with some unclear how 
they would respond if faced with selective termination decisions. 
In these instances, being a member of an already affected family 
could serve to heighten existing tensions that surround prenatal 
screening and testing practices (Kelly, 2009). More specifically, the 
negotiation of the fine balance between managing a sense of genetic 
responsibility for future family members’ health and a desire not to 
express disvalue towards affected family members, a concern that 
has been identified in relation to various different genetic conditions 
within the literature (Kay & Kingston, 2002; Kelly, 2009; Raspberry 
& Skinner, 2010; Shakespeare, 2006).
Although participants’ experiential knowledge emerged as an 
influence capable of both clarifying and muddying the waters of se‐
lective reproduction, the remaining four participants in the sample 
however, approached their reproductive decisions from an entirely 
different vantage point. For these participants, thalassaemia was 
first encountered not through the tangible and visible processes of 
symptoms and diagnosis, but rather through the far more abstract 
pathway of genetic screening.
8.2 | “With carriers, it's not a major thing is it? 
You just carry on normal…”: Prenatal screening, 
experience and reproductive decision‐making
Of	the	15	participants	in	this	study,	four	discovered	the	thalassaemia	
trait in their family through a genetic screening programme rather 
than through the illness and subsequent diagnosis of a family mem‐
ber. Three of these participants were informed of their carrier status 
following antenatal screening during their first pregnancy (Jahida, 
Arjun and Ameena), and one described discovering their child's tha‐
lassaemia following a heel prick test at birth (Fadwa). Of the three 
who discovered their carrier status through antenatal screening, two 
(Jahida and Arjun) had a first born child with thalassaemia.
One participant, Ameena, however, while discovering her carrier 
status (and that of her husband Sadeed) through antenatal genetic 
screening during her first pregnancy, declined all diagnostic testing 
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and went on to have two unaffected girls before her third child, a 
son named Taysir (aged five at the time of interview), was diagnosed 
with thalassaemia at birth. Aged 38 at time of interview, Ameena 
was working full time and living with her husband, extended family 
and four children in the North‐West of England. Due to Ameena's 
work schedule and that of her husband, their extended family—es‐
pecially Ameena's two younger sisters—were heavily involved in the 
care of the children.
In comparison to his three sisters (all of whom carry the thalas‐
saemia trait but do not have the condition), Taysir's life was de‐
scribed by Ameena as “hard”, marked by high medical and support 
needs and regular (every 3–4 weeks) transfusions in hospital to‐
gether with daily chelation therapy. Ameena described the monthly 
transfusions as particularly traumatic before Taysir had a permanent 
port implanted to facilitate access to his veins. In spite of this, how‐
ever, thalassaemia treatment remained a difficult and taxing process 
for Taysir and the wider family as Ameena described:
…[…]…and	then	every	night,	because	his	iron	is	high,	
because he has regular blood transfusions, his iron 
builds up so we've got to do iron chelation every night. 
He's on Desferal, it's like injecting him every night in 
the legs. Now his legs are sort of bruised; we could 
do	it	on	his	stomach	but	he's	got	no	fat	there…So	it's	
always on the legs, poor lad, he knows it's cream time 
when I have to put cream on and then after that poor 
kid, inject him. He's just so used to it, poor lad, and 
sometimes it does hurt him because sometimes I have 
to take the needle out because it's like swollen up for 
some odd reason, we don't know why. and then I put 
it	in	a	different	place.	But…	it's	horrible.
Ameena stressed throughout her interview that thalassaemia is a 
“very serious” condition that negatively impacted all spheres of fam‐
ily life. She described not only the administration of his treatment re‐
gime, but also the side effects of it (osteoporosis and weakened tooth 
enamel) and the constant anxiety surrounding the possibility of him 
receiving contaminated blood via transfusion as all contributing to 
Taysir's ongoing poor health, the strains placed on family life and con‐
sequently her negative perceptions of the condition overall.
Despite articulating a clear view throughout her account that 
thalassaemia is a serious condition that involves implicit suffering, 
Ameena's intimate, in‐depth and ongoing experiences of having a 
child with thalassaemia were in stark contrast to her earlier under‐
standing of the condition at the point of her first encounter with it, 
during her first pregnancy. Discovering both she and Sadeed were 
carriers through antenatal screening, Ameena acknowledged the 
lack of resonance with her life and family experiences that thalas‐
saemia had at that time:
I'll be honest, you know when I got pregnant and they 
were saying, “you're a carrier, and he's [Sadeed, hus‐
band] a carrier and you might have a chance of having 
a major” [affected child], at that point in time I just 
didn't realise how severe it was or how it would affect 
me or my child, you know. I just fobbed it off like, ‘oh 
you	know,	they	say	a	lot	of	things…’	and	I	didn't	think	
much	of	it..[…]…And	then	my	first	two	[children]	were	
carriers,	so	I	was	like,	‘oh	it's	okay,	you	know,	so	like…’	
and then he [Taysir, third child] turned out to be the 
major.	And	they	told	us	when	he	was	little….[…]…And	
even then it didn't sort of click to me and I thought, 
you know, okay, because I'd never read about it, I 
didn't know exactly what it was, I'd never seen any‐
body with thalassaemia, I didn't even know it ran in 
the families at all. Because some of them were abroad 
and I wasn't too much in contact with my dad, so I 
didn't know much about it. And then they did a blood 
test about two months old and they said he's really 
low in iron, we need to do his first blood transfusion, 
and I cried my eyes out. And that's when it hit me, 
yeah	…that	there's	something	severely	wrong	here.
Although the identification of carriers in the antenatal period 
has been heralded as expanding reproductive autonomy and choice 
for would‐be parents (Locock & Kai, 2008; Tsianakas, Atkin, Calnan, 
Dormandy, & Marteau, 2011), it can nevertheless be a frightening and 
bewildering experience for pregnant women and their partners (Beard 
et	al.,	2016;	Ioannou	et	al.,	2015;	Locock	&	Kai,	2008).	As	many	women	
are not aware that carrier screening for thalassaemia is taking place, or 
regard the screen as a compulsory component of high quality prenatal 
care (Cousens et al., 2010), the discovery of carrier couple status for 
a genetic condition completely unknown to them has been described 
as akin to entering a “new world” (McClaren et al., 2008) of genetic 
disease.
It was in the context of these liminal spaces that emerged 
through the discovery of carrier status that participants’ experi‐
ences and knowledge of health and illness gained significance in the 
formulation of their responses to their genetic risk (Archibald et al., 
2009; McClaren et al., 2008). As an autosomal recessive disorder, 
each “at risk” pregnancy conceived by a carrier couple has a one in 
four	(25%)	chance	of	being	affected	by	thalassaemia.	In	the	face	of	
this uncertainty, participants looked to their family histories and 
those of their friends and wider communities (“I'd never seen anyone 
with thalassaemia before”), together with own encounters with health 
and disease (“I just always felt I was healthy and so would have healthy 
children”) as well as their perceptions of their child's health to es‐
timate the significance of that genetic risk. The fact that Ameena 
had never heard of thalassaemia before was pivotal to her estima‐
tion of the scale of the threat (“If it was that bad, you'd know about it, 
wouldn't you?”). Together with the fact that her first two daughters 
were born healthy carriers of the condition, Ameena's experiences 
bolstered her in her conviction that thalassaemia was not something 
to be overly concerned about—this was something she could “safely 
ignore”. It was upon witnessing Taysir's deterioration and his subse‐
quent reliance on blood transfusions that Ameena felt the reality of 
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the condition really “hit home”. It was in the context of this acquired 
experiential knowledge that Ameena approached her fourth preg‐
nancy with revised understandings of her genetic responsibility, 
undergoing diagnostic testing and going on to have an unaffected 
(carrier) daughter.
Like Ameena, Arjun and Fadwa also opted to undergo prenatal 
diagnosis in subsequent pregnancies after experiencing thalassae‐
mia directly through their first born child, both receiving clear re‐
sults on those tests and going on to have three unaffected daughters 
and one unaffected son respectively. However, direct experience of 
thalassaemia did not change the reproductive decisions of all par‐
ticipants in this group in such a dramatic way as was observed with 
Ameena, Fadwa and Arjun.
Jahida was 33 years old at the time of her interview, a working 
mother of three children aged between 14 and nine, all of whom 
were diagnosed with thalassaemia at birth. Although Jahida was in‐
formed of her carrier status (and that of her husband, Parvez) during 
her first pregnancy, Jahida nevertheless felt the genetic risk to her 
children was minimal:
To be honest I never ever heard of it [thalassaemia] 
before. I only found out when I was first pregnant 
with my eldest one, I had a blood test and they told 
me at that point. That was the first time I actually 
heard of it, but to be honest I didn't really take much 
notice of it because I didn't think it was going to hap‐
pen to me, I kind of thought, “oh, okay”. And they said 
it's one out of four chances. And I was quite young 
myself and because I'd never heard of it, I didn't re‐
search into it and it turned out to be, you know, that 
actually	she	was	born	with	it…[…]…They	did	call	us	in	
to do a bit of counselling and went through this con‐
dition, but to be honest I still didn't take it seriously at 
all because I'd just never heard of it and I thought, one 
in four chance, I thought, well three chances it won't 
happen, so I was quite positive, but you never know.
Although Jahida's daughter, Aaleyah, was diagnosed with 
thalassaemia at birth, her symptoms remained relatively mild and 
she did not require blood transfusions until she was 4 years old. 
It was during this time of symptom stability and good health that 
Jahida and Parvez had their second child (Miras), opting not to use 
prenatal diagnosis:
I thought, “no, well Aaleyah was fine” and we were giv‐
ing her a healthy diet and she was still managing, so we 
kind of went into that belief that she would be okay 
and it won't happen to us twice and she will probably 
just be severely anaemic and we just need to give her 
a little extra support but she won't need transfusions. 
So then obviously I had my son [Miras], but eventually 
after that Aaleyah went onto it [blood transfusions] at 
four years old, then a year later he went onto it.
Due to Aaleyah's relatively good health, Jahida's perception of 
thalassaemia was initially largely benign, a viewpoint she reported 
as being upheld by her husband and wider family. Indeed, despite a 
confirmed diagnosis of thalassaemia, the continuation of Jahida's con‐
viction that “it won't happen to us” is striking. It was only after the initia‐
tion of blood transfusions for both of her children, Aaleyah and Miras, 
that Jahida's view of thalassaemia, and consequently her perception 
of the genetic risk to future family members, began to change. Jahida 
approached her third pregnancy with a profound sense of “genetic 
responsibility” (Kenen, 1994; Raspberry & Skinner, 2010) to prevent 
transmission of the condition, although ultimately her decision con‐
trasted sharply with that of Ameena, Arjun and Fadwa:
…..By	now[third	pregnancy]	I	was	worried	yeah	and	I	
was	offered	a	test	[prenatal	diagnosis,	CVS	test]…[…]…
they said they had to like put a needle in and check it 
from the stomach and then they will tell me there and 
then. But they said “there's a risk of miscarriage”. So I 
prepared myself everything for it, went for the coun‐
selling, actually went on the day to the hospital. And 
I got there and I just changed my mind at that point 
because I think I was three months along and I just 
thought, “I can't do it, because what if it is healthy and 
I end up losing it?” So I was like in so many different 
minds that I couldn't carry on. And then when she was 
born and they told me [that she has thalassaemia] I 
was really upset again, but either way I wouldn't want 
to lose any of my children anyway, so I just carried on.
Authors such as Lippman (1999) and Katz Rothman (1986) have 
highlighted the burden of responsibility that the emergence of ge‐
netic technologies confers on pregnant women. The availability of 
such technologies, delivered under the rubric of standard antenatal 
care, expands ideals of responsible motherhood by subsuming within 
them responsibility for the (genomic) health of future generations. 
As Reed has noted, the boundaries of this “genetic responsibility” are 
contoured through the lens of racial and gendered politics, reflecting 
a congruence of inequitable relations beyond the domain of repro‐
duction (Reed, 2011). For mothers of children with genetic disorders, 
such as Jahida, however, this sense of genetic responsibility took on 
very particular meaning and significance. As Kelly (2009) discovered, 
mothers of children with genetic disorders often consciously side‐step 
subsequent reprogenetic decision‐making so as not to be put in the 
fraught position of needing to choose between continuing with an af‐
fected pregnancy or aborting a foetus with the same condition as their 
existing child. For Jahida, declining the CVS test was ultimately not a 
rejection of her sense of reproductive genetic responsibility, but rather 
an alternative expression of it, whereby providing her child with the 
opportunity to live was prioritised over her felt responsibility to pre‐
vent thalassaemia.
For both Jahida and Ameena, therefore, as well as the other two 
participants in the sample who discovered their thalassaemia status 
through a screening result, experiential knowledge of thalassaemia 
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was pivotal to the interpretation and processing of their genetic risk 
information. Without grounding in their everyday realities, their car‐
rier screening results lacked meaning and context and were conse‐
quently disregarded, a situation which Ameena regarded as common:
….you	know	I	think	there	could	be	a	lot	of	women	out	
there like me who don't pay much attention. I remem‐
ber a few years back it was on TV and it used to be 
on so much, you know, adverts about it. But it never 
pointed, clicked to me or it didn't stand out to me until 
I had experience of it. So maybe if there was some‐
thing out there that really sort of clicked with every‐
one	and	sort	of	made	them	aware	of	it,	then	I've	just…	
Because	 if	 I'd	have	known	before…	oh	I	don't	know,	
this	is	it,	I'm	still	a	bit	confused	about	that…[…]….I	just	
don't believe in abortion. But maybe if I'd have done it 
a different way, like IVF or something.
Although Ameena did, in fact, know her carrier status before hav‐
ing her four children, her assertion that she would have acted differ‐
ently had she fully “known” and understood the experiential reality 
of life with genetic disease starkly highlights the dearth of accessible 
information on genetic disorders available to would‐be parents facing 
carrier screening results. Moreover, her account also draws attention 
to the intrinsic limitations of genetic risk information in the absence 
of an experiential “anchor” with which to ground the information in a 
person's everyday life.
9  | DISCUSSION
As genetic technologies continue to advance in their sophistication 
and capabilities, there are calls to expand genetic carrier screening 
panels for increasing numbers of genetic conditions. It has been ar‐
gued that such a move will accord prospective parents—especially 
carrier parents—more autonomy and control over their reproductive 
outcomes than has previously ever been possible (Henneman et al. 
(ESHG)., 2016). Such shifts, however, also entail the reconfiguration 
of ideals of responsible parenthood and justice as reproductive out‐
comes which previously fell under the auspices of chance or luck 
come to be considered controllable and amenable to human manipu‐
lation (Denier, 2014).
Acknowledgement of the high (combined) prevalence of ge‐
netic disorders, the decreasing cost and increasing ease of ge‐
netic screening, together with the dearth of effective treatments 
for even the most common genetic disorders have all served to 
heighten these calls for their prevention through screening pro‐
grammes. However, within the UK, thalassaemia remains the 
only genetic condition for which a prenatal carrier screening pro‐
gramme exists. This study, to the best of our knowledge, presents 
the first analytic comparison between the perspectives of those 
who discovered their family's thalassaemia trait through a screen‐
ing programme, and those whose reproductive views emerged 
from their everyday stocks of knowledge acquired through being 
part of an affected family. A consideration of the differences, but 
also the similarities between the perspectives of these two groups 
is critical as it highlights some of the implications when reproduc‐
tive decision‐making is transferred from already affected families 
to members of the public through the use of genetic screening 
programmes.
For those participants whose reproductive views and decisions 
emerged from a rich familial or personal history with thalassaemia, 
experiential knowledge was critical to the way in which they for‐
mulated their perceptions of their genetic risk, envisaged future 
generations affected by thalassaemia and ascertained where their 
reproductive responsibilities lay. While for some participants (e.g., 
Imran) this sense of responsibility was first and foremost to prevent 
the transmission of thalassaemia to the next generation others pre‐
sented more ambivalent views, conflicted by the inherent contra‐
dictions between their over‐arching sense of responsibility to future 
generations (to prevent genetic disease) and their daily experience of 
thalassaemia, which for many was described as “not so bad” (Mahila). 
First‐hand experience was constructed by all of these participants, 
therefore, as a privileged form of insight held by thalassaemic fami‐
lies (Mahila) that both improved the quality and authenticity of repro‐
ductive decision‐making, even as it could complicate the decisions 
made. Indeed, this was the case even in instances whereby its fal‐
libility as a knowledge resource was acknowledged, or its usage led 
to ambiguity or conflicted understanding of parental responsibility.
For participants who discovered they were carriers of thalas‐
saemia through prenatal or newborn genetic screening, however, 
perceptions of genetic risk and responsibility were constructed in 
entirely different ways. All four participants who discovered their 
carrier status in this way reported that their antenatal (or newborn) 
screening result was their first encounter with thalassaemia, having 
never heard of it before, nor met anyone with it. In the absence of 
this direct experience, this sub‐set of participants turned to a range 
of different resources to make sense of, and estimate the seriousness 
of, their genetic risk. Experiences with personal and familial health, 
of community and faith practices, the stories and views of family 
and friends together with internet resources and medical informa‐
tion were all drawn upon by this group to aid the interpretation and 
appraisal of their genetic risk. Ultimately, three out of four of these 
participants decided to proceed with their first pregnancies without 
further testing, a process that resulted in the births of two children 
with thalassaemia and one child with thalassaemia trait. As Etchegary 
et al. (2008) have observed, in the absence of “vivid” forms of knowl‐
edge about a condition (i.e., direct experience of the condition), peo‐
ple facing antenatal screening typically turn to more “vague” forms 
of experiential knowledge (such as the stories of unknown others) to 
make sense of their genetic risk. However, as demonstrated by the 
participants in this study, vague and vivid forms of knowledge were 
not equally valued, nor comparable in terms of their impact on repro‐
ductive views and decisions. Rather, these forms of knowledge were 
hierarchically ordered, with lived experience “trumping” all other 
forms of knowing. Indeed, for all four participants in this group, it 
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was the onset of serious thalassaemia symptoms in their child (rather 
than the thalassaemia diagnosis itself, or the concomitant provision 
of medical information) that had the most profound effect in the re‐
ordering of previously held beliefs and expectations of the condition. 
Experiential knowledge emerged as having the most significant, and 
enduring, impact on genetic risk perceptions, re‐calibrating partic‐
ipants’ sense of reproductive accountability, even as this account‐
ability could lead to entirely polarised reproductive decisions and 
outcomes in practice (e.g., Jahida vs. Arjun).
10  | CONCLUSIONS
Although uptake of thalassaemia carrier screening within the UK 
population is high, indeed it has been suggested that many pregnant 
women are not even aware it is even being carried out or consider 
it a mandatory part of prenatal care (Cousens et al., 2010), the reac‐
tions of shock and disbelief to positive screen results both within 
this study and the wider literature highlight the difficulties pregnant 
women and their partners have in assimilating into the world of ge‐
netic disease in the absence of prior experience of the condition. For 
Jahida and Ameena, for example, lack of family history with thalas‐
saemia, ambivalence about pregnancy termination, positive percep‐
tions of their own health and having had previously healthy children 
all contributed to the diminished sense of importance they assigned 
to their screening results and their perceived irrelevance to their 
lives. These reasons mirror those documented in the literature on 
screening refusal more broadly (Ioannou et al., 2014). It is notewor‐
thy that for both women, the lack of resonance that their screening 
results had even persisted following the diagnosis of thalassaemia in 
their child. Indeed, it was only following the onset of symptoms (that 
were serious enough to require treatment) that significant shifts 
occurred in the perceptions of thalassaemia, and correspondingly, 
in participants’ estimations of their genetic risk and responsibility. 
This finding underscores the centrality of direct experience to the 
interpretation of, and reaction to, abstract ideas such as genetic risk. 
Experiential knowledge brought thalassaemia out of the realm of the 
hypothetical and abstract and into the everyday lives of these par‐
ticipants in a way that genetic risk statistics and diagnoses could not. 
Research into the reactions of members of the general population to 
carrier screening have highlighted the difficulties in absorbing and 
relating to medical information about a condition that one has not 
directly encountered (Archibald et al., 2009; Beard et al., 2016). As 
such, bringing genetic disease “into the worlds” of the general public 
who largely view it as the domain of small groups of affected families 
has been identified as a key challenge in the successful implementa‐
tion of carrier screening programmes (McClaren et al., 2008).
11  | PR AC TICE IMPLIC ATIONS
This study highlights the particular difficulties facing people who 
discover their carrier status through genetic screening as opposed 
to through the symptoms and diagnosis of a family member. As has 
been described elsewhere in the literature, the participants who 
fell into this group faced unique challenges when assessing the rel‐
evance and significance of their results in the context of the rest of 
their lives (Archibald et al., 2009; Beard et al., 2016; Ioannou et al., 
2012;	Wright	et	al.,	2015).	This	was	particularly	the	case	for	partici‐
pants who already had healthy children and who had never before 
heard of thalassaemia, but also those whose experience of the con‐
dition was limited to a very mildly affected or pre‐symptomatic child 
(e.g., Jahida).
The experiential knowledge of affected individuals and families 
is a significant, yet under‐utilised, resource that may be harnessed in 
the context of genetic counselling in order to address some of these 
difficulties. It has been suggested that insights from affected families 
could be imparted to genetic counselling patients through a variety 
of means; for example, through personal stories, photographs, vi‐
gnettes, videos and interviews, all of which may assist in humanising 
and “bringing to life” a genetic condition in a way that the imparta‐
tion of purely clinical information often fails to do (Ahmed, Bryant, & 
Hewison, 2007). Support and advocacy groups for already affected 
families may be a particularly important resource in developing and 
evaluating these resources. There is limited published data exploring 
the usage of these groups by individuals and couples identified as 
carriers, particularly those facing complex decisions about invasive 
diagnostic testing and/or selective pregnancy termination. For well‐
established screening programmes, like that for Down's Syndrome 
for example, however, such avenues of support and information are 
well‐developed and used (Down's Syndrome Association, 2017). The 
lack of correspondingly well‐developed mechanisms of information 
and support within the groups for genetic disorders, such as thalas‐
saemia, may be explained by the relative rarity of these conditions in‐
dividually, the (already strained) resources of such groups and also by 
the somewhat ambiguous character of carrier status. Carrier status 
has been described by Timmermans and Buchbinder (2010) as analo‐
gous to a liminal state, a halfway house between health and disease, 
the significance of which can be difficult to interpret. Carrier cou‐
ples may struggle to reconcile this ambiguity in their identities which, 
in turn, may render them alienated from such groups, the ethos of 
which may also clash with their own reactions to their genetic status.
12  | RESE ARCH RECOMMENDATIONS
Further research is indicated to explore understandings of, and 
reactions to, genetic risk among the general population, particu‐
larly in relation to different types of genetic screening programme 
(pre‐conceptual, prenatal, newborn) and for contrasting conditions. 
Anticipating (and responding appropriately to) the information and 
support needs of the screened population has been described as par‐
amount to the successful implementation of screening programmes. 
This is especially the case, as has been demonstrated by this 
study and others (e.g., Evers‐Kiebooms, Denayer, & Berghe, 1990; 
Hershberger et al., 2012), where information needs fluctuate across 
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the couple's decision‐making trajectory and use of genetic technolo‐
gies is inconsistent across pregnancies (e.g., Jahida). Unlike screening 
for non‐heritable disorders like Down's Syndrome where a positive 
result is typically a “one off” event (and therefore contact with the 
support group may be fleeting), genetic risk for conditions like tha‐
lassaemia recurs (assuming the same reproductive partner for each 
pregnancy), suggesting a need for ongoing forms of information and 
support that are tailored to its unique, and expanding, challenges.
Additional research could also explore the format and content 
of educational resources around genetic disease that people under‐
going genetic carrier screening find most useful at different time 
points in their reproductive journey. Indeed, at a time when panel 
screens for a range of genetic conditions are emerging on the hori‐
zon of standard NHS antenatal care (Nuffield Council on Bioethics, 
2017p. 84), a greater understanding of the way such information 
is processed and formulated into conceptualisations of different 
genetic disorders, as well as responses to genetic risk, is now of 
paramount importance.
13  | STUDY LIMITATIONS
Recruiting participants through the UKTS may have introduced bias 
to the sample as its members have typically received a diagnosis 
of thalassaemia in the family. Indeed, all four participants who dis‐
covered their thalassaemia carrier status through prenatal screen‐
ing went on to have affected children. The perspectives of those 
who received a negative prenatal test result, or who terminated 
their pregnancy following a positive result, therefore, are missing. 
Although such individuals may be recruited through antenatal clin‐
ics, there are ethical concerns with undertaking interviews in the 
(typically highly strained and short) time between receiving a posi‐
tive screening result and undergoing a prenatal diagnosis/selective 
pregnancy termination. However, as the focus of this analysis was 
not on the outcomes of the reproductive views and decisions per se, 
but rather on the processes and resources with which participants ar‐
rived at them, it was felt that the exclusion of these participants did 
not detract significantly from the utility of its findings.
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